Parasite | Eso | Sto | Cancer | ESD
001 | 101 | 201 | 301 | 401 | 501 | 601 | 701 | 801 | 901 | 1000
HCC·Î ¼ö¼ú ÈÄ follow up Áß alpha-fetoproteinÀÌ »ó½ÂµÈ ȯÀÚÀÔ´Ï´Ù. PET¿¡¼ ÀÌ»óÀÌ ¹ß°ßµÇ¾ú°í ³»½Ã°æÀ» ÇÏ¿´½À´Ï´Ù. À§ Á¶Á÷°Ë»ç ¸é¿ªÇü±¤°Ë»ç¿¡¼ AFP ¾ç¼ºÀ¸·Î ³ª¿Ô½À´Ï´Ù.
¾Æ·¡·Î
¾Æ·¡·Î
¾Æ·¡·Î
¾Æ·¡·Î
¾Æ·¡·Î
Hepatoid adenocarcinoma´Â Á¶Á÷ÇÐÀûÀ¸·Î´Â adenocarcinoma¿Ü¿¡ °£¼¼Æ÷¼º ºÐȸ¦ º¸ÀÌ´Â ºÎºÐÀÌ µ¿ÀÏ ¾ÏÁ¾ ³»¿¡ °øÁ¸Çϸé¼, ³ôÀº Ç÷Áß alpha-fetoprotein(AFP)Ä¡¸¦ º¸ÀÌ´Â ¾ÏÁ¾ÀÔ´Ï´Ù. 1985³â Ishikura¿¡ ÀÇÇØ Ã³À½À¸·Î ¸í¸íµÇ¾ú½À´Ï´Ù. °£¼¼Æ÷¼º ºÐȸ¦ º¸ÀÌ´Â »ù¾ÏÁ¾Àº À§Àå°ü, ³¼Ò, Æó, ´ã³¶, ÀÚ±Ã, ¹æ±¤ µîÀÇ ¿©·¯ ºÎÀ§¿¡¼ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. À§¿¡ ¹ß»ýÇÑ °£¼¼Æ÷¾ç »ù¾ÏÁ¾Àº Áø´Ü ´ç½Ã ÁøÇàµÈ °æ¿ì°¡ ¸¹À¸¸ç ³ôÀº ÀüÀÌÀ²°ú ºÒ·®ÇÑ ¿¹Èĸ¦ º¸ÀÔ´Ï´Ù (Âü°í¹®Çå : Korean J Med 2007;73:107-111)
À§ ȯÀÚ´Â HCCÀÇ stomach metastasis¿Í °¨º°ÀÌ ÇÊ¿äÇÏ¿´Áö¸¸ (1) ¼ö³â°£ °£¾ÏÀÇ Àç¹ßÀÌ ¾ø¾ú´ø Á¡, (2) ³»½Ã°æ À°¾È¼Ò°ß¿¡¼ metastatic disease º¸´Ù ¿ø¹ß¼º À§¾ÏÀÇ Æ¯Â¡À» º¸ÀÌ´Â Á¡ ¹× (3) adenocarcinomaÀÇ component°¡ ÀÖ¾ú´ø Á¡À» °í·ÁÇÏ¿© primary gastric hepatoid adenocarcinoma·Î Áø´ÜÇÏ¿´°í ¼ö¼úÀ» ÇÏ¿´½À´Ï´Ù.
À§¼±¾Ï¿¡ hepatoid differentiationÀ» º¸ÀÌ´Â ºÎºÐÀÌ ¾ó¸¶³ª Æ÷ÇԵǾî¾ß hepatoid adenocarcinoma·Î Áø´ÜÇÒ ¼ö Àִ°¡¿¡ ´ëÇÑ ±âÁØÀº Á¤ÇØÁ® ÀÖÁö ¾Ê½À´Ï´Ù. Hepatoid differentiationÀ» º¸ÀÌ´Â ºÎÀ§¸¦ ÀϺΠ°¡Áö°í ÀÖ´Â À§¼±¾ÏÀº ÀûÁö ¾Ê½À´Ï´Ù.
2014. 5. 11. ÀÌÁØÇà
ÀÏÀü¿¡ hepatoid adenocarcinoma Áõ·Ê(À§¾Ï26)¸¦ º¸³»µå¸° ¹Ù ÀÖ½À´Ï´Ù. ÀÌ¿¡ ´ëÇÏ¿© ÇÑ ¾Öµ¶ÀÚ²²¼ "4³âÂ÷ ¶§ ´ëÇÑ°£ÇÐȸ Áõ·Êº¸°íÇß´ø ÄÉÀ̽º(Clinical and Molecular Hepatology 2013;19:173-178)°¡ ÀÖ¾î ÷ºÎÇÕ´Ï´Ù. °£¾ÏÀ¸·Î Ä¡·á¹Þ°í NETR (no evidence of tumor recurrence) »óÅ¿¡¼ ÃßÀû Áß AFP »ó½Â, CT »ó lymphadenopathy ¸¸ º¸¿© °£¾Ï Àç¹ßÀ» ÀǽÉÇß½À´Ï´Ù. ¹æ»ç¼±Ä¡·á¸¦ °í·ÁÇÏ¿´°í ¿ì¿¬È÷ pre-RT screening EGD Áß À§¾ÏÀ» ¹ß°ßÇÏ°í Á¶Á÷°Ë»ç¿¡¼ hepatoid adenocarcinoma¸¦ Áø´ÜÇÑ »ç·ÊÀÔ´Ï´Ù. "AFP »ó½Â ½Ã intrahepatic lesionÀÌ ¾øÀ¸¸é EGD¸¦°í·ÁÇØ¾ß ÇÑ´Ù"¶ó´Â ³»¿ëÀ¸·Î ½è½À´Ï´Ù."¶ó´Â ¸ÞÀÏÀ» Áּ̽À´Ï´Ù. °¨»çÇÕ´Ï´Ù. ¼Ò°³ÇÕ´Ï´Ù.